An interventional study of deep transcranial magnetic stimulation (dTMS) and Theta burst stimulation (TBS) in Obsessive - Compulsive Disorder, sponsored by ASST Fatebenefratelli Sacco. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by ASST Fatebenefratelli Sacco · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Obsessive-Compulsive Disorder with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Obsessive-Compulsive Disorder · Italy.
Among the 14 studies in Obsessive-Compulsive Disorder with a site in Italy, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 with no phase, and was the 12th registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →5 of the 14 studies in Obsessive-Compulsive Disorder with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18–45
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Sites in Italy
Ages 18+
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 12–20
Carmen Concerto · Sites in Italy
Ages 18–55 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 3
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 37 across the 10 interventional studies, 342 across the 4 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
ASST Fatebenefratelli Sacco is the lead sponsor of 38 studies on the registry; 12 are open to participants now.
ASST Fatebenefratelli Sacco has 1 study filed under Obsessive-Compulsive Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Obsessive-Compulsive Disorder with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07488663ASST Fatebenefratelli SaccoMODELING OBSESSIVE COMPULSIVE DISORDER AND EXPLORING TREATMENT RESPONSE USING INNOVATIVE THERAPIES AND STEM CELLS | 2027-01 |
| NCT06724029Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNeurosurgical Outcome Network | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Obsessive-Compulsive Disorder with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study focuses on people with obsessive-compulsive disorder (OCD) who do not respond well to standard treatments. Researchers aim to understand why some patients respond to medications or brain stimulation therapies, while others do not. The study will include 60 patients grouped by their treatment response:
Adults (18-65 years old) with obsessive-compulsive disorder (OCD) recruited at two specialized clinics in Milan (Luigi Sacco Hospital) and Monza (IRCCS Fondazione San Gerardo Monza). After a complete explanation of the study, everyone will provide written informed consent and have a diagnostic interview to confirm OCD. People with seizures/epilepsy or certain implanted devices (e.g., pacemaker, intracranial metal clips) will not be enrolled.
Procedures:
Grouping by medication response:
Responders (20 people): OCD symptoms improve with serotonin reuptake inhibitors (SRIs).
Treatment-resistant (40 people): OCD symptoms did not improve after multiple SRI trials (including SSRIs and clomipramine at recommended doses).
Randomized brain stimulation for treatment-resistant OCD:
The 40 treatment-resistant participants are randomly assigned (1:1) to Theta-Burst TMS (TBS) or Deep TMS (d-TMS), following established safety guidelines.
Medications remain stable during TMS. Symptom changes are measured with the Y-BOCS at baseline and follow-up. Participants are classified as responders or non-responders to TBS or d-TMS.
After treatment, people fall into five subgroups: SRI Responders, d-TMS Responders, TBS Responders, d-TMS Non-Responders, TBS Non-Responders.
Blood samples and lab modeling:
A small blood sample is used to create patient-derived stem cells (hiPSCs) and then striatal neurons (medium spiny neurons, MSNs) in the lab.
These neurons help us study how brain cells from different patient groups respond to medicines and stimulation.
Mimicking brain stimulation in the lab:
Researchers use optogenetics (safe light pulses) to activate the lab-grown neurons, mirroring the effects of TMS.
They also use well-known medicines that turn up or down dopamine signaling (e.g., D1/D2 agonists/antagonists) to see how neurons react.
Changes in synaptic proteins and cell activity are measured with standard lab techniques.
Using RNA sequencing, the team looks at which genes are "on" or "off" in neurons from different patient groups-before and after light stimulation-to discover molecular signatures linked to treatment response or resistance.
Findings are checked and confirmed with additional lab tests.
Study results analysis
The study includes 60 participants in total. Data are analyzed with standard statistical methods to compare groups and treatments. Lab experiments use multiple independent preparations to ensure reliable results.
Study outcomes:
By combining careful clinical assessments with cutting-edge cell models, this study aims to discover biological markers that can predict who will benefit from medicines and from innovative TMS protocols (TBS or d-TMS)-helping move toward more personalized care for OCD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm includes patients classified as resistant to pharmacological treatment, clear evidence of treatment resistance (defined as the absence of a significant clinical response after at least two treatment trials with SSRIs and one trial with clomipramine each administered for a minimum of 12 weeks at the maximum recommended dose). Patients will undergo d-TMS protocol for 5 weeks of daily treatments, 5 days a week and 4 treatments during the 6th week, and a 4-week follow-up phase.
Device: deep transcranial magnetic stimulation (dTMS)
This arm includes patients classified as resistant to pharmacological treatment, clear evidence of treatment resistance (defined as the absence of a significant clinical response after at least two treatment trials with SSRIs and one trial with clomipramine each administered for a minimum of 12 weeks at the maximum recommended dose). Patients from this group will undergo the TBS protocol at the OCD clinic, ASST Fatebenefratelli Sacco of Milan, consisting in one week of daily treatments and a 4-weeks follow-up phase.
Device: Theta burst stimulation (TBS)
The d-TMS protocol will be performed at the treatment-resistant disorders clinic, IRCCS San Gerardo Monza, and will consist of 5 weeks of daily treatments, 5 days a week and 4 treatments during the 6th week, and a 4-week follow-up phase, following most recent clinical studies. d-TMS will be administered using a TMS stimulator equipped with an H-shaped coil (Harmelech et al., 2021). The coil will be placed 4 cm anterior to the foot motor cortex and used at 100% of the leg resting motor threshold (RMT), defined as the coil position that elicited the minimal involuntary contractions of the feet (3 of 6 attempts). The stimulation of the area localized 4 cm anterior to the foot motor cortex targets the dorsal medial prefrontal cortex (mPFC) and the anterior cingulate cortex (ACC) bilaterally. Patients will receive 20 Hz d-TMS at 100% of RMT, with 2-second pulse trains and 20-second intertrain intervals, for a total of 50 trains and 2,000 pulses per session.
TBS will be administered using a Magstim Rapid2 stimulator. 3-pulse 50-Hz bursts will be given to patients' left orbitofrontal cortex every 200 ms (at 5 Hz) at an intensity of 80% of the active motor threshold, defined as the coil position that elicited a right thumb movement while stimulating the left primary motor cortex. The treatment will consist of 2 sessions per day, thirty minutes apart, for 5 days in a week. Following the parameters of previous studies, each session will deliver a burst of three pulses at 50 Hz and repeated every 200 ms (at 5 Hz) for a total of 600 pulses lasting 40s (Oberman et al., 2011). A total of 1200 pulses will be delivered per day.
Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score
The primary outcome is the change in Y-BOCS total score from baseline to the end of treatment, used to assess clinical response to TBS versus d-TMS in treatment-resistant OCD patients.
Time frame: Baseline to 10 weeks (end of treatment and follow-up)
Clinical response rate
Proportion of participants achieving a reduction ≥20% in Y-BOCS total score after TMS treatment.
Time frame: Baseline to end of follow-up (4 weeks post-treatment)
Change in Clinical Global Impression (CGI) scores
Change in CGI-Severity and CGI-Improvement scores from baseline to post-treatment.
Time frame: Baseline to 10 weeks
Change in Hamilton Depression Rating Scale (HDRS)
Change in depressive symptom severity measured by HDRS.
Time frame: Baseline to end of follow-up (4 weeks post-treatment)
Change in Hamilton Anxiety Rating Scale (HARS)
Change in anxiety symptom severity measured by HARS.
Time frame: Baseline to end of follow-up (4 weeks post-treatment)
Molecular and cellular characterization of patient-derived neurons
Assessment of morphological, biochemical, and transcriptomic profiles of hiPSC-derived medium spiny neurons from participants, including differential gene expression and response to stimulation.
Time frame: From baseline (sample collection) to completion of laboratory analyses (up to 36 months)
Treatment response classification
Classification of participants into responders and non-responders to TBS or d-TMS based on predefined Y-BOCS thresholds.
Time frame: Baseline to end of follow-up (4 weeks post-treatment)
Plan to share: No
Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.
Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 45 months is close to that.
Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →
ASST Fatebenefratelli Sacco